Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ReDiscover-2: Zovegalisib + Fulvestrant vs Capivasertib + Fulvestrant in HR+/HER2- Advanced Breast Cancer
NCT06982521Phase 3Recruiting
- Sponsor
- Relay Therapeutics
- Start
- Aug 2025
- Primary completion
- Apr 2028
- Modality
- Small Molecules
- Countries
- 27
01
Overview
Phase 3, randomised, open-label trial of zovegalisib in breast cancer (2 arms), sponsored by Relay Therapeutics. Primary endpoint: Progression-Free Survival. Started Aug 2025; status: recruiting.
02
Drugs
zovegalisib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06982521.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06982521.